Market Reengagement Despite past controversies related to deceptive practices and bribery issues, Valeant Pharmaceuticals has demonstrated a focus on product innovation and market re-entry, particularly with the launch of new medications such as flibanserin (Addyi). This indicates potential openness to new pharmaceutical collaborations or distribution partnerships.

Strategic Acquisitions Valeant's history of significant acquisitions, including Bausch + Lomb and AcneFree, showcases an active growth strategy through mergers and acquisitions. Business development opportunities could involve supplying or partnering for over-the-counter dermatology products or eye care solutions aligning with their portfolio.

Large Customer Base With a workforce estimating up to 5,000 employees and revenue in the $1 billion to $10 billion range, Valeant maintains a substantial market presence. This presents opportunities to tailor offerings across hospital, retail, and specialty pharmacies that serve their broad customer network.

Technology and Data Use Utilizing tools like Google Analytics and Microsoft ASP.NET indicates a focus on data-driven decision-making and digital engagement. Partnering with digital health platforms or providing data management solutions could enhance Valeant’s digital transformation initiatives.

Emerging Opportunities Given Valeant’s association with innovative dermatology and ophthalmology products and its recent focus on re-establishing trust, there is potential to introduce new pharmaceuticals, health technologies, or specialized medical devices that support their product pipeline and improve patient outcomes.